Endologix, Inc. (ELGX) Analysts See $-0.20 EPS on February, 20

Endologix, Inc. (NASDAQ:ELGX) Corporate Logo
Big Money Sentiment decreased to 1.15 in 2018 Q3. It has change of 0.20, from 2018Q2’s 1.35. The ratio dived due to Endologix, Inc. positioning: 18 sold and 23 reduced. 21 funds took positions and 26 increased positions. Investors holded 77.82 million in 2018Q2 but now own 76.15 million shares or 2.15% less.
Financial Bank Of Ny Mellon Corp holds 358,185 shs or 0% of its capital. California Pub Employees Retirement reported 83,600 shs. Marshall Wace Llp holds 124,729 shs or 0% of its capital. Credit Suisse Ag invested in 0% or 31,247 shs. State Common Retirement Fund accumulated 0% or 1.47 million shs. Ameritas Invest Prtn invested in 7,000 shs or 0% of the stock. Services Automobile Association accumulated 88,121 shs. Paloma Prtnrs Mgmt Co, Connecticut-based fund reported 96,500 shs. Spark Inv Ltd Co reported 0.01% stake. Palisade Limited Nj, a New Jersey-based fund reported 1.59M shs. Nea Mngmt Ltd, Maryland-based fund reported 2.49 million shs. Bankshares Of Montreal Can owns 574 shs. Principal Fincl, a Iowa-based fund reported 28,115 shs. Alliancebernstein Limited Partnership accumulated 113,057 shs. Parametric Portfolio Associates Lc invested in 202,537 shs or 0% of the stock.

Investors wait Endologix, Inc. (NASDAQ:ELGX)’s quarterly earnings on February, 20., according to Faxor. Analysts predict 150.00 % diference or $-0.20 from the $-0.08 EPS from 2018. 33.33 % negative EPS growth is what Wall Street’s sees after $-0.15 reported EPS last quarter. Ticker’s shares touched $0.5803 during the last trading session after 2.81% change.Endologix, Inc. has volume of 391,129 shares. Since February 14, 2018 ELGX has declined 87.86% and is downtrending. The stock underperformed the S&P500 by 87.86%.

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally.The company has $60.03 million market cap. It offers minimally-invasive endovascular repair products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.Last it reported negative earnings. The firm also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens.

For more Endologix, Inc. (NASDAQ:ELGX) news brought out briefly go to: Zacks.com, Seekingalpha.com, Nasdaq.com, Streetinsider.com or Businesswire.com. The titles are as follows: “Endologix (ELGX) Reports Q3 Loss, Tops Revenue Estimates – Zacks.com” brought out on November 01, 2018, “Endologix down 9% premarket on Nellix recall – Seeking Alpha” on January 04, 2019, “WellCare Health (WCG) Q4 Earnings Beat Estimates, Soar Y/Y – Nasdaq” with a publish date: February 06, 2019, “Endologix (ELGX) Announces Decision to ‘Cease Immediately’ the ‘Unrestricted Sales and Use of the Nellix System,’ Outside of Clinical Protocol – StreetInsider.com” and the last “Endologix Provides Update on Previously Announced Voluntary Nellix System Recall – Business Wire” with publication date: January 22, 2019.

Endologix, Inc. (NASDAQ:ELGX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.